Published April 12, 2022 | Version v1
Dataset Open

Psychiatric manifestations and associated risk factors among hospitalized patients with COVID-19 in Edo State, Nigeria: A Cross-sectional Study

Description

The Coronavirus Disease 2019 (COVID-19) has had devastating effects globally. These effects are likely to result in mental health problems at different levels. Although studies have reported the mental health burden of the pandemic on the general population and frontline health workers, the impact of the disease on the mental health of patients in COVID-19 treatment and isolation centres have been understudied in Africa.

We estimated the prevalence of depression and anxiety and associated risk factors in hospitalized persons with COVID-19. A cross-sectional survey was conducted among 489 patients with COVID-19 at the three government-designated treatment and isolation centres in Edo State, Nigeria. The 9-item Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) tool were used to assess depression and anxiety respectively. Binary logistic regression was applied to determine risk factors of depression and anxiety. Results Of the 489 participants, 49.1% and 38.0% had depressive and anxiety symptoms respectively. The prevalence of depression, anxiety, and combination of both were 16.2%, 12.9% and 9.0% respectively. Moderate-severe symptoms of COVID-19, ≥14 days in isolation, worrying about the outcome of infection and stigma increased the risk of having depression and anxiety. Additionally, being separated/divorced increased the risk of having depression and having comorbidity increased the risk of having anxiety.

A substantial proportion of our participants experienced depression, anxiety and a combination of both especially in those who had the risk factors we identified. The findings underscore the need to address modifiable risk factors for psychiatric manifestations early in the course of the disease and integrate mental health interventions and psychosocial support into COVID-19 management guidelines. --

Notes

Funding provided by: PANDORA-ID-NET funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme*
Crossref Funder Registry ID:
Award Number: EDCTP Reg/Grant RIA2016E-1609

Files

Files (58.8 kB)

Name Size Download all
md5:d141240bcac7c2afe9193dbfe7ae6a7f
12.2 kB Download
md5:7467c3c0e9717f45902c53455bd5bddb
46.6 kB Download

Additional details

Related works